Thymosin Alpha-1: The Immune Peptide With a Real Prescription Pad

Most peptides people talk about live in a research-only zone. Thymosin Alpha-1 doesn't. It's approved as Zadaxin in more than 35 countries, it's been given to over half a million patients, it's used alongside chemo in oncology wards, and it has real Phase III hepatitis data. The gap between what this peptide can actually do and how often people in biohacking circles mention it is one of the bigger asymmetries in the catalog.

What it is, in one paragraph

Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide first pulled out of calf thymus tissue in 1977 by Allan Goldstein's group. It's the body's own immune-regulation peptide — signaling through TLR9 and TLR2 on dendritic cells, bumping Type I interferon production, maturing antigen-presenting cells, and rebalancing cytokine storms. The clinical use cases are chronic hepatitis B, adjunct cancer immunotherapy, severe sepsis, and (off-label, controversially) COVID-19. Among research peptides, it has the deepest human clinical footprint of any you'll encounter.

Dosing: what people actually do

Community dosing roughly tracks the clinical Zadaxin protocol, sometimes a bit more aggressive.

• Clinical (Zadaxin): 1.6 mg sub-Q, twice weekly
• Community starting: 300 mcg daily for week 1
• Maintenance: 500 mcg daily, weeks 2–12
• Immune reconstitution protocol: 1.6 mg twice weekly for 8–12 weeks
• Cycle: 8–12 weeks, break 4–8 weeks, repeat if needed

Reconstitute a 5 mg vial with 3 mL BAC → ~1,667 mcg/mL. 500 mcg = 30 units on a U-100 syringe.

"Ran Ta1 during a bad winter — the usual two rounds of 'dying for three days' never showed up. N=1, sure, but it's the kind of winter I can actually remember now." — forum user

What it pairs with

Ta1 is the immune arm. Its stack partners depend on what you're doing.

Goal	Stack
Chronic immune load / infection recovery	Ta1 solo or with BPC-157 (gut repair)
Cancer immunotherapy adjunct	Prescribed, with checkpoint inhibitors / chemo — not a DIY protocol
General "immune resilience"	Ta1 + TB-500 (both from thymosin fraction 5)
Post-chemo or post-illness recovery	Ta1 + BPC-157 + a GHRH/GHRP stack

Anti-aging protocols sometimes include Ta1 alongside Epithalon on the theory that immune-system aging (immunosenescence) is a core pillar of general aging. That's reasonable but not well-proven for peptides specifically.

Red flags and side effects

Given the clinical population that's taken this — half a million patients — the safety profile is remarkably clean:

• Injection site reactions — mild, the most common AE in every trial
• Low-grade fatigue in the first few doses
• Mild flu-like feelings — transient, rare

What doesn't show up: significant organ toxicity, CYP interactions, or the complicated side effects that come with actual immunomodulators like interferon.

One caveat the community raises: autoimmune conditions. Ta1 ramps up the immune system. For someone with active autoimmune disease, that direction may be wrong. This is a real medical-consult situation, not a forum question.

The honest limits

• Quality variability. Research-grade Ta1 is not pharmaceutical Zadaxin. Lyophilized content, purity, and acetylation (which matters for activity) vary between suppliers. Get a COA
• Indications beyond the approved ones are evidence-lite. The hepatitis B data is strong. The COVID data is retrospective and contested. The "general immune support" use case is plausible but not proven at the level the clinical indications are
• Dose uncertainty. The 1.6 mg twice-weekly Zadaxin dose is the only one with real human data. The daily 300–500 mcg community protocol is reasonable but extrapolated

Where to go next

• For the full immunology mechanism, clinical trial landscape, and Zadaxin history, see the Pepperpedia Thymosin Alpha-1 entry
• Real-world Ta1 protocols and autoimmune edge-case discussion live in the Optimization forum
• Pair with the TB-500 field guide — both come from thymosin fraction 5, but they do very different jobs